Antibodies

05 Jun 2020 European Commission Grants Marketing Authorisation for DARZALEX (daratumumab) Subcutaneous Formulation for all Currently Approved Daratumumab Intravenous Formulation Indications
05 Jun 2020 Jounce Therapeutics Regains Worldwide Rights to JTX-8064 from Bristol Myers Squibb
03 Jun 2020 Sanofi European Commission approves Sarclisa® (isatuximab) for adults with relapsed and refractory multiple myeloma
03 Jun 2020 Aduro Biotech Presents Nonclinical and Phase 1 Healthy Volunteer Data for BION-1301 at the 57th ERA-EDTA Virtual Congress
03 Jun 2020 Y-mAbs Announces U.S. FDA Acceptance of Biologics License Application for Danyelza™ (naxitamab) for the Treatment of Neuroblastoma for Priority Review
03 Jun 2020 Sarclisa® (isatuximab) combination therapy demonstrated superior progression free survival and clinically meaningful depth of response in patients with relapsed multiple myeloma
03 Jun 2020 Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study
02 Jun 2020 FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer
02 Jun 2020 Innovent Announces the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study
02 Jun 2020 Harbour BioMed Receives Chinese Regulatory Approval of IND Application to Begin Seamless Phase 2/3 Clinical Trial of HBM9161 in Graves’ Ophthalmopathy
01 Jun 2020 Compugen Announces FDA Clearance of IND Application for Phase 1/2 Triple Combination Study of COM701 with Bristol Myers Squibb's Opdivo® (Nivolumab) and TIGIT Inhibitor
01 Jun 2020 Henlius and Accord Receive Positive CHMP Opinion for Oncology Biosimilar, HLX02 (Trastuzumab)
01 Jun 2020 Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans
01 Jun 2020 Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
01 Jun 2020 Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
01 Jun 2020 Celltrion Announces Positive Pre-clinical Results for COVID- 19 Antiviral Antibody Treatment, Showing Improvement in Recovery Time
31 May 2020 Harpoon Therapeutics Presents Interim Phase 1 Data from an Ongoing Dose Escalation Trial for the PSMA-targeting TriTAC® HPN424 at the ASCO20 Virtual Scientific Program
31 May 2020 CytomX Therapeutics Clinical Programs Highlighted at American Society of Clinical Oncology ASCO20 Virtual Scientific Program
30 May 2020 Bird Rock Bio Files IND Application for Phase 2 Study of Nimacimab for Treatment of Renal Diseases
30 May 2020 Amphivena Presents Data from First-in-Human Study of AMV564 in Solid Tumor Patients at the ASCO Virtual Annual Meeting 2020
30 May 2020 Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
30 May 2020 FDA Approves Genentech’s Tecentriq in Combination With Avastin for People With the Most Common Form of Liver Cancer
30 May 2020 SAB Biotherapeutics Confirms Neutralizing Antibodies to SARS-CoV-2 and Begins Clinical Manufacturing of Novel COVID-19 Therapeutic Candidate
29 May 2020 Alteogen Presents the First-in-Human Data on ALT-P7, a HER2-targeting Antibody-Drug Conjugate (ADC) at ASCO 2020
29 May 2020 Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top